Acupath Laboratories Offers 24-48 Hour Turnaround Time on COVID-19 TESTING
Multiplex RT PCR Testing for all 3 coronavirus genes
PLAINVIEW, N.Y., August 18, 2020 – Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, now offering COVID-19 testing utilizing the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit.
With results available within 24 – 48 hours, Acupath’s test is highly sensitive, as it is one of the few labs targeting regions of three coronavirus genes; orf-1ab, S gene, and N gene. Acupath provides fast results in time for elective procedures while offering an extensive panel of anatomic pathology services.
With the dedicated, hard-working staff, Acupath is consistently working to provide fast, accurate, and personalized services to their clients.
“I have had the privilege of using Acupath Pathology services for many years. The quality of their reports, their customer service, there IT know how for reporting is number one. Just when I thought they couldn’t get better, they started offering very quick turnaround Covid test results. This is essential for my practice in the current requirements for elective procedures. They are always there for the doctor and especially the patient!”
– Sam Moskowitz MD, FACP, FACG, AGAF
“I want to thank you and Acupath for the exceptional service you have provided for my practice with regards to COVID testing. As you said, I get results in 24-36 hours without fail, usually it’s closer to 24 hours. Acupath has provided excellent service with my pathology samples and I was not surprised that they were able to do just as good a job with COVID.”
– Paul Cohen, MD
For more information, email [email protected].
About Acupath Laboratories, Inc.
Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women’s Health, Otolaryngology, Podiatry, and Hematology / Oncology. Acupath offers an extensive test menu on both a global and TC/PC basis, processes well over 150,000 specimens annually, and is the first lab worldwide to offer URO17™, an innovative new immunocytochemistry test for the detection of bladder cancer, recently designated as a “Breakthrough Device” by the FDA.